|1 Reiser R: Saturated fat in the diet and serum cholesterol concentration: a critical examination of the literature. Am J Clin Nutr 1973;26:524–555.
2 Mensink RP, Katan MB: Effect of dietary fatty acids on serum lipids and lipoproteins. A meta- analysis of 27 trials. Arterioscler Thromb Vasc Dis 1992;12:911–919.
3 Hegsted DM, Ausman LM, Johnson JA, Dallal GE: Dietary fat and serum lipids: an evaluation of the experimental data. Am J Clin Nutr 1993; 57:875–883.
4 Woodside JV, Kromhout D: Fatty acids and CHD. Proc Nutr Soc 2005;64:554–564.
5 Kuller LH: Nutrition, lipids, and cardiovascular disease. Nutr Rev 2006;64:S15–S26.
6 Lapointe A, Balk EM, Lichtenstein AH: Gender differences in plasma lipid response to dietary fat. Nutr Rev 006;64:234–249.
7 Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg FJ, Liem AH, et al: The contribution of classical risk factors to cardiovascular disease in familial hyperchole-sterolaemia: data in 2400 patients. J Intern Med 004;256:482–490.
8 Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipo-proteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003;77:1146–1155.
9 Ravnskov U: The questionable role of saturated and poly-unsaturated fatty acids in cardiovascular disease. J Clin Epidemiol 1998;51:443–460.
10 Shaper AG: Cardiovascular studies in the Samburu tribe of northern Kenya. Am Heart J 1962;63:437–442.
11 Lapiccirella V, Lapiccirella R, Abboni F, Liotta S: Enquete clinique, biologique et cardiographique parmi les tribus nomades de la Somalie qui se nourissent seulement de lait. Bull World Hlth Org 1962;27:681–697.
12 Mann GV, Shaffer RD, Sandstead HH: Cardiovascular disease in the Masai. J Atheroscl Res 1964;4:289–312.
13 Ramsay LE, Yeo WW, Jackson PR: Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991;303:953–957.
14 Noakes M, Foster PR, Keogh JB, James AP, Mamo JC, Clifton PM: Comparison of isocaloric very low carbohydrate/ high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. Nutr Metab 2006;3:7.
15 Meckling KA, O’Sullivan C, Saari D: Comparison of a low-fat diet to a lowcarbohy- drate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular dis- ease in free-living, overweight men and women. J Clin Endocrinol Metab 2004;89:2717–2723.
16 Sondike SB, Copperman N, Jacobson MS: Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents. J Pediatr 2003;142:253–258.
17 Sharman MJ, Gomez AL, Kraemer WJ, Volek JS: Very low-carbohydrate and low-fat diets affect fasting lipids and postprandial lipemia differently in overweight men. J Nutr 2004;134:880–885.
18 Hays JH, DiSabatino A, Gorman RT, Vincent S, Stillabower ME: Effect of a high saturated fat and no-starch diet on serum lipid subfractions in patients with documented atherosclerotic cardio- vascular disease. Mayo Clin Proc 2003;78: 1331–1336.
19 Westman EC, Yancy WS, Edman JS, Tomlin KF, Perkins CE: Effect of 6-month adherence to a very low carbohydrate diet program. Am J Med 2002;113:30–36.
20 Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary BG, Rader DJ, Edman JS, Klein S: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082–2090.
21 Yancy WS Jr, Foy M, Chalecki AM, Vernon MC, Westman EC: A lowcarbohydrate, keto- genic diet to treat type 2 diabetes. Nutr Metab 2005;2:34–40.
22 Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF: A randomized study comparing the effects of a low-carbo- hydrate diet and a conventional diet on lipoprotein sub- fractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004;117: 398–405.
23 Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA: A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 2003;88:1617–1623.
24 Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT: Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr 2006; 83:1025–1031.
25 Keys A: Coronary heart disease in seven countries. Circulation 1970;41(suppl 1):1–211.
26 Leosdottir M, Nilsson PM, Nilsson JA, M.nsson H, Berglund G: Dietary fat intake and early mortality patterns – data from The Malmö Diet and Cancer Study. J Intern Med 2005;258: 153–165.
27 Stemmermann GN, Hayashi T, Resch JA, Chung CS, Reed DM, Rhoads GG: Risk factors related to ischemic and hemorrhagic cerebro- vascular disease at autopsy: the Honolulu Heart Study. Stroke 1984;15:23–28.
28 Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: inci- dence of stroke in Japan and Hawaii. Stroke 1984;15:15–23.
29 McGee D, Reed D, Stemmerman G, Rhoads G, Yano K, Feinleib M: The relationship of dietary fat and cholesterol to mortality in 10 years: the Honolulu Heart Program. Int J Epidemiol 1985;14:97–105.
30 Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA: Inverse association of dietary fat with development of ischemic stroke in men. JAMA 1997;278:2145–2150
31 Ross RK, Yuan JM, Henderson BE, Park J, Gao YT, Yu MC: Prospective evaluation of dietary and other predictors of fatal stroke in Shanghai, China. Circulation 1997;96:50–55.
32 Seino F, Date C, Nakayama T, Yoshiike N, Yokoyama T, Yamaguchi M, Tanaka H: Dietary lipids and Incidence of cerebral infarction in a Japanese rural community. J Nutr Sci Vitaminol 1997;43:83–99.
33 Iso H, Stampfer MJ, Manson JE, Rexrode K, Hu F, Hennekens CH, Colditz GA, Speizer FE, Willett WC: Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. Circulation 2001;103:856–863.
34 He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A: Dietary fat intake and risk of stroke in male US health- care professionals: 14 year prospective cohort study. BMJ 2003;327:777–782.
35 Iso H, Sato S, Kitamura A, Naito Y, Shima- moto T, Komachi Y: Fat and protein intakes and risk of intraparenchymal hemorrhage among middle-aged apanese. Am J Epidemiol 2003; 157:32–39.
36 Sauvaget C, Nagano J, Hayashi M, Yamada M: Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality in the adult health study. Stroke 2004;35:1531–7.
37 Smedman AE, Gustafsson IB, Berglund LG, Vessby BO: Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999;69:22–29.
38 Wolk A, Furuheim M, Vessby B: Fatty acid composition of adipose tissue and serum lipids are valid biological markers of dairy fat intake in men. J Nutr 2001;131:828–833.
39 Rosell M, Johansson G, Berglund L, Vessby B, de Faire U, Hellenius ML: Associations bet- ween the intake of dairy fat and calcium and ab- dominal obesity. Int J Obes Relat Metab Disord 2004;28:1427–1434
40 Brevik A, Veierod MB, Drevon CA, Andersen LF: Evaluation of the odd fatty acids 15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat. Eur J Clin Nutr 2005; 59:1417–1422.
41 Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J: Relationship between carbohydrate-induced hypertriglyce- ridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res 2000;41:595–604.
42 Kirkeby K, Ingvaldsen P, Bjerkedal I: Fatty acid composition of serum lipids in men with myocardial infarction. Acta Med Scand 1972; 192:513–519.
43 Wood DA, Butler S, Riemersma RA, Thomson M, Oliver MF, Fulton M, Birtwhistle A, Elton R: Adipose tissue and platelet fatty acids and coronary heart disease in Scottish men. Lancet 1984;2:117–121.
44 Kark JD, Kaufmann NA, Binka F, Goldberger N, Berry EM: Adipose tissue n-6 fatty acids and acute myocardial infarction in a population con- suming a diet high in polyunsaturated fatty acids. Am J Clin Nutr 2003;77:796–802.
45 Clifton PM, Keogh JB, Noakes M: Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 2004;134:874–879.
46 Pedersen JI, Ringstad J, Almendingen K, Haugen TS, Stensvold I, Thelle DS: Adipose tissue fatty acids and risk of myocardial infarction–a case-control study. Eur J Clin Nutr 2000;54:618–25.
47 Lang PD, Degott M, Heuck CC, Opherk D, Vollmar J: Fatty acid composition of adipose tissue, blood, lipids, and glucose tolerance in patients with different degrees of angiographi- cally documented coronary arteriosclerosis. Res Exp Med 1982;180:161–168.
48 Reed DM, Resch JA, Hayashi T, MacLean C, Yano K: A prospective study of cerebral artery atherosclerosis. Stroke 1988;19:820–825.
49 Hooper L, Summerbell CD, Higgins JP, Thompson RL, Capps NE, Smith GD, Riemersma RA, Ebrahim S: Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 2000;322:757–763.
50 Ravnskov U: Diet-heart disease hypothesis is wishful thinking. BMJ 2002;324:238.
51 Watts GF, Jackson P, Burke V, Lewis B: Dietary fatty acids and progression of coronary artery disease in men. Am J Clin Nutr 1996; 64:202–209.
52 Bemelmans WJ, Lefrandt JD, Feskens EJ, Broer J, Tervaert JW, May JF, Smit AJ: Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MAR- GARIN) study. Am J Clin Nutr 2002;75:221–227
53 Mozaffarian D, Rimm EB, Herrington DM: Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am J Clin Nutr 2004;80:1175–1184.
54 de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454–1459.
55 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354: 447–455.
56 Landé KE, Sperry WM: Human athero- sclerosis in relation to the cholesterol content of the blood serum. Arch Pathol 1936;22:301–312.
57 Paterson JC, Dyer L, Armstrong EC: Serum cholesterol levels in human atherosclerosis. Can Med Ass J 1960;82:6–11.
58 Mathur KS, Patney NL, Kumar V, Sharma RD: Serum cholesterol and atherosclerosis in man. Circulation 1961;23: 847–852.
59 Marek Z, Jaegermann K, Ciba T: Athero- sclerosis and levels of serum cholesterol in postmortem investigations. Am Heart J 1962; 63:768–774.
60 Schwartz CJ, Stenhouse NS, Taylor AE, White TA: Coro-nary disease severity at necropsy. Br Heart J 1965;27;731–739.
61 Méndez J, Tejada C: Relationship between serum lipids and aortic atherosclerotic lesions in sudden accidental deaths in Guatemala City. Am J Clin Nutr 1967;20:1113–1117.
62 Rhoads GG, Blackwelder WC, Stemmer- mann GN, Hayashi T, Kagan A: Coronary risk factors and autopsy findings in Japanese- American men. Lab Invest 1978;38:304–311.
63 Feinleib M, Kannel WB, Tedeschi CG, Landau TK, Garrison RJ: The relation of antemortem characteristics to cardiovascular findings at necropsy. The Framingham Study. Atherosclerosis 1979;34:145–157.
64 Sadoshima S, Kurozumi T, Tanaka K, et al: Cerebral and aortic atherosclerosis in Hisa- yama, Japan. Atherosclerosis 1980;36:117–126
65 Oalmann MC, Malcom GT, Toca VT, Guzman MA, Strong JP: Community pathology of atherosclerosis and coronary heart disease: post mortem serum cholesterol and extent of coronary atherosclerosis. Am J Epidemiol 1981;113:396–403.
66 Sorlie PD, Garcia-Palmieri MR, Castillo- Staab MI, Costas R, Oalmann MC, Havlik R: The relation of antemortem factors to athero- sclerosis at autopsy. The Puerto Rico Heart Health Program. Am J Pathol 1981;103:345–352.
67 Cabin HS, Roberts WC: Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary artery narrowing by atherosclerotic plaque in coronary heart disease. Am J Med 1982;73:227–234.
68 Solberg LA, Strong JP, Holme I, Helgeland A, Hjerman I, Leren P, Mogensen SB: Stenoses in the coronary arteries. Relation to atheroscle- rotic lesions, coronary heart disease, and risk factors. The Oslo Study. Lab Invest 1985;53: 648–655.
69 Solberg LA, Hjermann I, Helgeland A, Holme I, Leren PA, Strong JP: Association between risk factors and atherosclerotic lesions based on autopsy findings in the Oslo study: a preliminary report; in Schettler G, Goto Y, Hata Y, Klose G (eds): Atherosclerosis IV. Proc 4 Int Symp. Berlin, Springer, 1977, pp 98–100.
70 Okumiya N, Tanaka K, Ueda K, Omae T: Coronary atherosclerosis and antecedent risk factors: pathologic and epidemiologic study in Hisayama, Japan. Am J Cardiol 1985;56:62–66.
71 Reed DM, Resch JA, Hayashi T, MacLean C, Yano K: A prospective study of cerebral artery atherosclerosis. Stroke 1988;19:820–825.
72 Reed DM, Strong JP, Resch J, Hayashi T: Serum lipids and lipoproteins as predictors of atherosclerosis. An autopsy study. Arterio- sclerosis 1989;9:560–564.
73 Ravnskov U: Is atherosclerosis caused by high cholesterol?QJM 2002;95:397–403.
74 Kramer JR, Kitazume H, Proudfit WL, Matsuda Y, Williams GW, Sones FM: Pro- gression and regression of coronary athero- sclerosis: relation to risk factors. Am Heart J 1983;105:134–144.
75 Bemis CE, Gorlin R, Kemp HG, Herman MV: Progression of coronary artery disease: a clini- cal arteriographic study. Circulation 1973;47: 455–464.
76 Kimbiris D, Lavine P, Van Den Broek H, Najmi M, Likoff W: Devolutionary pattern of coro- nary atherosclerosis in patients with angina pectoris. Coronary arteriographic studies. Am J Cardiol 1974;33:7–11.
77 Shub C, Vlietstra RE, Smith HC, Fulton RE, Elveback LR: The unpredictable progression of symptomatic coronary artery disease: a serial clinical-angiographic analysis. Mayo Clin Proc 1981;56:155–160.
78 Anderson KM, Castelli WP, Levy D: Chole- sterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257: 2176–2180.
79 Dagenais GR, Ahmed Z, Robitaille NM, Gingras S, Lupien PJ, Christen A, Meyer F, Rochon J: Total and coronary heart disease mortality in relation to major risk factors. Quebec Cardiovascular Study. Can J Cardiol 1990;6:59–65.
80 Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglycerid- aemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tole- rance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabe- tologia 1989;32:300–304.
81 Uusitupa MI, Laakso M, Sarlund H, Majander H, Takala J, Penttilä I: Effects of a very-low- calorie diet on metabolic control and cardiovas- cular risk factors in the treatment of obese non- insulin-dependent diabetics. Am J Clin Nutr 1990;51:768–773.
82 Fitzgerald AP, Jarrett RJ: Are conventional risk factors for mortality relevant in type 2 diabetes? Diabet Med 1991;8:475–480.
83 Ford ES, DeStefano F: Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol 1991;133:1220–1230.
84 Laakso M, Lehto S, Penttilä I, Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421–1430.
85 Janghorbani M, Jones RB, Gilmour WH, Hedley AJ, Zhianpour M: A prospective popu- lation based study of gender differential in mortality from cardiovascular disease and ‘all causes’ in asymptomatic hyperglycaemics. J Clin Epidemiol 1994;47:397–405.
86 Collins VR, Dowse GK, Ram P, Cabealawa S, Zimmet PZ: Non-insulin-dependent diabetes and 11-year mortality in Asian Indian and Mela- nesian Fijians. Diabet Med 1996;13: 125–132.
87 Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R: Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with noninsulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997;96: 1750–1754.
88 Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI: Hyper-glycemia and compositional lipopro- tein abnormalities as predictors of cardiovascu- lar mortality in type 2 diabetes: a 15-year follow- up from the time of diagnosis. Diabetes Care 1998;21:1861–1869.
89 Hänninen J, Takala J, Keinänen- Kiukaanniemi S: Albuminuria and other risk factors for mortality in patients with non-insulin- dependent diabetes mellitus aged under 65 years: a population-based prospective 5-year study. Diabetes Res Clin Pract 1999;43: 121–126.
90 Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ: Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 2000;148:159–169.
91 Ostgren CJ, Lindblad U, Melander A, Råstam L: Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 2002;25: 1297–302.
92 Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, Crepaldi G, Fedele D, Manzato E: Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis 2003;13:46–51.
93 Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, Osaki R, Cockram CS, Chan JC: Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 2005;21:183–188.
94 Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R: Plasma concentration of asymmetrical dimethyl- arginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113–2117.
95 Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, Timio M: Inflammation, infection and cardio-vascular events in chronic hemodialysis atients: a prospective study. J Nephrol 2003;16:245–251.
96 Gertler MM, et al: Long-term follow-up study of young coronary patients. Am J Med Sci 1964;247:145–155.
97 Frank CW, et al: Angina pectoris in men. Prognostic significance of selected medical factors. Circulation 1973;47:509–517.
|98 Mulcahy R, et al: Factors influencing long-term prognosis in male patients surviving a first coronary attack. Br Heart J 1975;37: 158–165.
99 Khaw KT, Barrett-Connor E: Prognostic factors for mortality in a population-based study of men and women with a history of heart disease. J Cardiopulm Rehab 1986;6:474–480.
100 Chester M, et al: Identification of patients at high risk for adverse coronary events while awaiting routine coronary angioplasty. Br Heart J 1995;73:216–222.
101 Behar S, et al: Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J 1997;18:52–59.
102 Jacobs D, Blackburn H, Higgins M, et al: Report of the conference on low blood chole- sterol: mortality associations. Circulation 1992;86:1046–1060.
103 Ravnskov U: High cholesterol may protect against infections and atherosclerosis. QJM 2003;96:927–934.
104 Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, Brunner D: Low total cholesterol is associated with high total mor- tality in patients withcoronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J 1997;18: 52–59.
105 Casiglia E, Spolaore P, Ginocchio G, Colangeli G, Di Menza G, Marchioro M, Mazza A, Ambrosio GB: Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol 1993;9:577–586.
106 Chyou PH, Eaker ED: Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000;29:69–74
107 Forette B, Tortrat D, Wolmark Y: Chole- sterol as risk factor for mortality in elderly women. Lancet 1989;1:868–870.
108 Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, Robbins JA, Gardin JM: Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998;279:585–592.
109 Harris T, Feldman JJ, Kleinman JC, Ettinger WH Jr,Makuc DM, Schatzkin AG: The low cholesterol mortality association in a national cohort. J Clin Epidemiol 1992;45: 595–601.
110 Jonsson A, Sigvaldason H, Sigfusson N: Total cholesterol and mortality after age 80 years. Lancet 1997;350:1778–1779.
111 Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF: Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272:1335–1340.
112 Räihä I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L: Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997;17: 1224–1232.
113 Rudman D, Mattson DE, Nagraj HS, Caindec N, Rudman IW, Jackson DL: Ante- cedents of death inthe men of a Veterans Administration nursing home. J Am Geriatr Soc 1987;35:496–502.
114 Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD: Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351–355.
115 Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R: Relationship between plasma lipids and all-cause mortality in non- demented elderly. J Am Geriatr Soc 2005;53: 219–226.
116 Siegel D, Kuller L, Lazarus NB, Black D, Feigal D, Hughes G, Schoenberger JA, Hulley SB: Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. Am J Epidemiol 1987;126:385–399.
117 Staessen J, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, et al: Is a high serum cholesterol level associated with longer survivalin elderly hypertensives? J Hypertens 1990;8:755–761.
118 Ulmer H, Kelleher C, Diem G, Concin H: Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health 2004;13: 41–53.
119 Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG: Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350: 1119–1123.
120 Akerblom JL, Costa R, Luchsinger JA, Manly JJ, Tang MX, Lee JH, Mayeux R, Schupf N: Relation of plasma lipids to all-cause morta- lity in Caucasian, African- American and Hispanic elders. Age Ageing 2008;37:207–213.
121 Miettinen TA, Gylling H: -Mortality and cholesterol metabolism in familial hyper- cholesterolemia. Longterm follow-up of 96 patients. Arteriosclerosis 1988;8:163–167.
122 Hill JS, Hayden MR, Frohlich J, Pritchard PH: Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hyper- cholesterolemia. Arterioscler Thromb 1991; 11:290– 7.
123 Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J: Coronary artery disease in hetero- zygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995;92:290–295.
124 Kroon AA, et al: The prevalence of peri- pheral vascular disease in familial hyperchole- sterolaemia. J Intern Med 1995;238:451–459.
125 Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SE: Evaluation of coronary risk factors in patients with heterozygous famlial hypercholesterolema. Am J Cardiol 2001;87:47–53.
126 de Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ: Prevalence and significance of cardiovas- cular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003;253:161–168.
127 Neil HA, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, et al: Established and emerging coronary risk factors in patients with heterozygous familial hyper- cholesterolaemia. Heart 2004;90:1431–1437.
128 Jansen AC, van Aalst-Cohen ES, Tanck MW, ChengS, Fontecha MR, Li J, et al: Genetic determinants of cardiovascular disease risk in familial hyperchole sterol- emia.Vasc Arterioscler Thromb Biol 2005;25:1475–1481.
129 Skoumas I, Masoura C, Pitsavos C, Tousoulis D,Papadimitriou L, Aznaouridis K, Chrysohoou C,Giotsas -N, Toutouza M, Tentolouris C, Antoniades C, Stefanadis C: Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with hetero- zygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol 2007; 121:178–183.
130 Postiglione A, Nappi A, Brunetti A, Soricelli A, Rubba P, Gnasso A, Cammisa M, Frusciante V, Cortese C, Salvatore M, et al: Relative protection from cerebral atheroscle- rosis of young patients with homozygous fa- milial hypercholesterolemia. Atherosclerosis 1991;90:23–30.
131 Rodriguez G, Bertolini S, Nobili F, Arrigo A, Masturzo P, Elicio N, Gambaro M, Rosadini G: Regional cerebral blood flow in familial hypercholesterolemia. Stroke 1994;25: 831–836.
132 Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223–261.
133 Neil HA, Hawkins MM, Durrington PN, Betteridge DJ, Capps NE, Humphries SE, Simon Broome Familial Hyperlipidaemia Re- gister Group and Scientific Steering Commit- tee: Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 2005;179:293–297.
134 Sugrue DD, Trayner I, Thompson GR, Vere TV, Dimeson J, Stirling Y, et al: Coronary artery disease and haemostatic variables in heterozygous familial hyper-cholesterolaemia. Br Heart J 1985;53:265–268.
135 Ravnskov U: Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992;305:15–19.
136 Ravnskov U: Implications of 4S evidence on baseline lipid levels. Lancet 1995;346:181.
137 Todd EW, Coburn AF, Hill AB: Antistreptolysin S titres in rheumatic fever. Lancet 1939;2:1213–1217.
138 Stollerman GH, Bernheimer AW: Inhibition of strepto-lysin S by the serum of patients with rheumatic fever and acute streptococcal pharyngitis. J Clin Invest 1950;29:1147–1155.
139 Humphrey JH: The nature of antistrepto- lysin S in the sera of man and of other species; the lipoprotein properties of antistreptolysin S. Br J Exp Pathol 1949;30: 365–375.
140 Stollerman GH, Bernheimner AW, MacLeod CM: The association of lipoproteins with the inhibition of streptolysin S by serum. J Clin Invest 1950;29:1636–1645.
141 Skarnes RC: In vivo interaction of endo- toxin with a plasma lipoprotein having esterase activity. J Bacteriol 1968;95:2031–2034.
142 Shortridge KF, Ho WK, Oya A, Kobayashi M: Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asian J Trop Med Public Health 1975;6:461–466.
143 Whitelaw DD, Birkbeck TH: Inhibition of staphylo-coccal delta-haemolysin by human serum lipoproteins. FEMS Microbiology Letters 1978;3:335–338.
144 Freudenberg MA, Galanos C: Interaction of lipopoly-saccharides and lipid A with comple- ment in rats and its relation to endotoxicity. Infect Immun 1978;19:875–882.
145 Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipoproteins. Isolation and charac-terization of a bacterial lipopolysaccharidehigh density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981;67:827–837.
146 Bhakdi S, Tranum-Jensen J, Utermann G, Fussle R: Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J Biol Chem 1983;258:5899–5904.
147 Seganti L, Grassi M, Mastromarino P, Pana A, Superti F, Orsi N: Activity of human serum lipoproteins on the infectivity of rhabdo- viruses. Microbiologica 1983;6:91–99.
148 Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA: The role of lipoproteins and receptormediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986;83:2704–2708.
149 Huemer HP, Menzel HJ, Potratz D, Brake B, Falke D, Utermann G, et al: Herpes simplex virus binds to human serum lipoprotein. Inter- virology 1988;29:68–76.
150 Flegel WA, Wölpl A, Männel DN, Northoff H: Inhi-bition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989;57:2237–2245.
151 Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS: Cytokine response by monocytes and macrophages to free and lipoproteinbound lipopoly-saccharide. Infect Immun 1990;58:2375–2382.
152 Northoff H, Flegel WA, Yurttas R, Wein- stock C: The role of lipoproteins in inactivation of endotoxin by serum. Beitr Infusionsther 1992;30:195–197.
153 Superti F, Seganti L, Marchetti M, Marziano ML, Orsi N: SA-11 rotavirus binding to human serum lipoproteins. Med Microbiol Immunol 1992;181:77–86.
154 Weinstock C, Ullrich H, Hohe R, Berg A, Baumstark MW, Frey I, et al: Low density lipoproteins inhibit endo-toxin activation of monocytes. Arterioscler Thromb 1992;12: 341–347.
155 Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H: Prevention of endotoxin- induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993;61:5140–5146.
156 Feingold KR, Funk JL, Moser AH, Shige- naga JK, Rapp JH, Grunfeld C: Role for cir- culating lipoproteins in protection from endo- toxin toxicity. Infect Immun 1995;63: 2041–2046.
157 Netea MG, Demacker PNM, Kullberg BJ, Boerman OC, Verschueren I, Stalenhoef AFH, et al: Lowdensity lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest 1996;97:1366–1372.
158 Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H: Serum total cholesterol and risk of hospitali- zation, and death from respiratory disease. Int J Epidemiol 1997;26:1191–1202.
159 Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Feingold KR: Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998;121:335–347.
160 Rauchhaus M, Coats AJ, Anker SD: The endotoxin- lipoprotein hypothesis. Lancet 2000;356:930–933.
161 Claxton AJ, Jacobs DR Jr, Iribarren C, Welles SL, Sidney S, Feingold KR: Asso- ciation between serum total cholesterol and HIV infection in a high-risk cohort of young men. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:51–57.
162 Neaton JD, Wentworth DN: Low serum cholesterol and risk of death from AIDS. AIDS 1997;11:929–930
163 Chen Z, Keech A, Collins R, Slavin B, Chen J, Campbell TC, Peto R: Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. BMJ 1993;306:890–894.
164 Fraunberger P, Hahn J, Holler E, Walli AK, Seidel D: Serum cholesterol levels in neutro- penic patients with fever. Clin Chem Lab Med 2002;40:304–307.
165 Elias ER, Irons MB, Hurley AD, Tint GS, Salen G: Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet 1997;68:305–310.
166 Sijbrands EJ, Westendorp RG, Defesche JD, de Meier PH, Smelt AH, Kastelein JJP: Mortality over two centuries in large pedigree with familial hypercholeste-rolaemia: family tree mortality study. BMJ 2001;322: 1019–1023.
167 Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR: Cancer incidence by levels of cholesterol. JAMA 1981;245:247–252.
168 Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55–60.
169 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
170 Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
171 Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–1009.
172 Shepherd J, Blauw GJ , Murphy MB, et al: Pravastatin in elderly individuals at risk of vas cular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623–1630.
173 Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hyper- cholesterolemia. Circ J 2002;66:1087–1095.
174 Iwata H, Matsuo K, Hara S, et al: Use of hydroxymethyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 2006;97:133–138.
175 Hansson GK: Inflammation, atheroscle- rosis, and coro-nary artery disease. N Engl J Med 2005;352:1685–1695.
176 Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, Rogers WJ, Merz CN, Sopko G, Pepine CJ: Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coro- nary artery disease: results from the NHLBI WISE study. Am Heart J 2001;141:735–741.
177 McCully KS: Vascular pathology of homo- cysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56: 111–128.
178 Ravnskov U, McCully KS: Vulnerable plaque formation from obstruction of vasa vasorum by homo-cysteinylated and oxidized lipoprotein aggregates complexed with micro- bial remnants and LDL autoanti-bodies. Ann Clin Lab Sci 2009;39:3–16.
179 Benesch R, Benesch RE: Thiolation of proteins. Proc Natl Acad Sci USA 1958;44: 848–853.
180 Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS: Thiolation of low-density lipoprotein by homo- cysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovas Dis 1994;64:70–77.
181 Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B: Generation and initial cha- racterization of a novel poly-clonal antibody directed against homocysteine thiolactone- modified low density lipoprotein. J Lipid Res 1998;39:925–933.
182 Heinecke JW, Suits AG, Aviram M, Chait A: Phago-cytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb 1991; 11:1643–1651.
183 Kalayoglu MV, Indrawati, Morrison RP, Morrison SG, Yuan Y, Byrne GI: Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000;181(suppl 3): S483–S489.
184 Qi M, Miyakawa H, Kuramitsu HK: Por- phyromonas gingivalis induces murine macro- phage foam cell formation. Microb Pathog 2003;35:259–267.
185 Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M, Hampe J, Sahly H, Reinecke A, Haake N, Gunther R, Kruger D, Lins M, Herrmann G, Folsch UR, Simon R, Schreiber S: Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006;113:29–37.
186 Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME: Cyto- megalovirus antigen within human arterial smooth muscle cells. Lancet 1983;2:644–647.
187 Pampou SY, Gnedoy SN, Bystrevskaya VB, Smirnov VN, Chazov EI, Melnick JL, DeBakey ME: Cytomegalo-virus genome and the immediate-early antigen in cells of different layers of human aorta. Virchows Arch 2000;436:539–552.
188 Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894–2900.
189 Madjid M, Naghavi M, Malik BA, Litovsky S Willerson JT, Casscells W: Thermal detec- tion of vulnerable plaque. Am J Cardiol 2002; 90:36L–39L.
190 Guyton JR, Klemp KF: Transitional features in human atherosclerosis. Intimal thickening, cholesterol clefts, and cell loss in human aortic fatty streaks. Am J Pathol 1993;143:1444–1457.
191 Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS, SHOCK Investigators: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005;165:1643–1650